CFDE Data Portal | Search FAM90A20

	Label	Description
	FAM90A20 Gene (Entity type)	ENSG00000233295 - family with sequence similarity 90 member A20
	GSE226285 3 V 0 GLUTATHIONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE187006 3 V 2 VALPROIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE169617 azacitidine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE169617 1 V 2 AZACITIDINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE174745 dopamine neuron 1 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE187006 0 V 1 VALPROIC ACID HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE203579 GSE203581 adenosine 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE145285 PRMT5 p53 inhibition RNA Messenger 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE219154 aspirin 4 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS

FAM90A20

ENSG00000233295 - family with sequence similarity 90 member A20

GSE226285 3 V 0 GLUTATHIONE HUMAN UP

A Gene Set from LINCS

GSE187006 3 V 2 VALPROIC ACID HUMAN UP

A Gene Set from LINCS

GSE169617 azacitidine 1 v 2 human up

A Gene Set from LINCS

GSE169617 1 V 2 AZACITIDINE HUMAN UP

A Gene Set from LINCS

GSE174745 dopamine neuron 1 v 8 human up

A Gene Set from LINCS

GSE187006 0 V 1 VALPROIC ACID HUMAN DN

A Gene Set from LINCS

GSE203579 GSE203581 adenosine 2 v 1 human dn

A Gene Set from LINCS

GSE145285 PRMT5 p53 inhibition RNA Messenger 0 v 1 human up

A Gene Set from LINCS

GSE219154 aspirin 4 v 2 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.